Many urology conditions can have a major impact on the quality of a patient’s everyday life, and with an aging population, patient numbers are predicted to grow. On top of this, emergency readmission rates are common within urology (1), with some procedures (such as cystectomy) are seeing average 30-day readmission rates of 24% in the UK (2).
To manage growing demand, urology departments must remain at the forefront of technological advancements. Peptide technology can provide a suitable, efficient solution to manage bleeding (a common cause of readmissions) and help to speed up procedure times, whilst maintaining prioritisation of the patient.
Within urology, PuraStat is indicated for haemostasis in the following situations encountered during surgery, when haemostasis by ligation or standard means is insufficient or impractical2:
Bleeding from small blood vessels and oozing from capillaries of the parenchyma and surrounding tissues of solid organs
Oozing from vascular anastomoses to native or artificial vessels, on the surface of blood vessels and surrounding tissues
1. NHS ‘Urology: GIRFT Programme National Specialty Report’, Simon Harrison, 2018. https://gettingitrightfirsttime.co.uk/wp-content/uploads/2018/07/GIRFT-Urology.pdf 2. PuraStat IFU-007 Rev 2
Collaboration Opportunities
Our R&D teams are always exploring new innovations and indications to expand our products so that we continue providing healthcare professionals with better services and patient outcomes. If you are interested in collaborating with us, please get in touch.
What is PuraStat?
Transparency, viscosity and its synthetic peptide composition are just some features that make PuraStat a suitable tool for urologists.
